We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, Exelixis (EXEL - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.42 per share, reflecting an increase of 147.1% compared to the same period last year. Revenues are forecasted to be $502.96 million, representing a year-over-year increase of 18.3%.
The consensus EPS estimate for the quarter has been revised 0.4% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some Exelixis metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts forecast 'Revenues- Net product' to reach $448.24 million. The estimate indicates a year-over-year change of +18.4%.
Analysts expect 'Revenues- Net product- CABOMETYX' to come in at $433.73 million. The estimate indicates a year-over-year change of +15.2%.
According to the collective judgment of analysts, 'Revenues- License' should come in at $44.61 million. The estimate indicates a year-over-year change of -0.2%.
Shares of Exelixis have experienced a change of +4.2% in the past month compared to the +11.3% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), EXEL is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
In its upcoming report, Exelixis (EXEL - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.42 per share, reflecting an increase of 147.1% compared to the same period last year. Revenues are forecasted to be $502.96 million, representing a year-over-year increase of 18.3%.
The consensus EPS estimate for the quarter has been revised 0.4% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some Exelixis metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts forecast 'Revenues- Net product' to reach $448.24 million. The estimate indicates a year-over-year change of +18.4%.
Analysts expect 'Revenues- Net product- CABOMETYX' to come in at $433.73 million. The estimate indicates a year-over-year change of +15.2%.
According to the collective judgment of analysts, 'Revenues- License' should come in at $44.61 million. The estimate indicates a year-over-year change of -0.2%.
View all Key Company Metrics for Exelixis here>>>
Shares of Exelixis have experienced a change of +4.2% in the past month compared to the +11.3% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), EXEL is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>